Clinical Trial Update: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nimotuzumab in combination with modified FOLFIRINOX/GX as postoperative adjuvant therapy for pancreatic cancer. It is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Modified FOLFIRINOX (modified FOLFIRINOX)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Pancreatic Cancer | Phase 2 | Status: RECRUITING